(Q53380063)

13 May 2018

title

Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease. (English)

1 reference

13 May 2018

0 references

1 reference

1 reference

13 May 2018

Benjamin T Black

0 references

Kristina F Zdanys

1 reference

13 May 2018

Timothy G Kleiman

1 reference

13 May 2018

Martha G MacAvoy

1 reference

13 May 2018

Tracy E Rightmer

1 reference

13 May 2018

Monique Grey

1 reference

13 May 2018

Katherine S Garman

1 reference

13 May 2018

Rajesh R Tampi

1 reference

13 May 2018

Christopher H van Dyck

1 reference

13 May 2018

language of work or name

English

0 references

publication date

12 July 2006

1 reference

13 May 2018

published in

Neuropsychopharmacology

1 reference

13 May 2018

volume

1 reference

13 May 2018

issue

1 reference

13 May 2018

page(s)

171-179

1 reference

13 May 2018

APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Delusions and hallucinations in Alzheimer's disease: review of the brain decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Metrifonate treatment of AD: influence of APOE genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Factors associated with psychotic symptoms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Influence of the apolipoprotein E type 4 allele on cerebral glucose metabolism in Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

The apolipoprotein E epsilon 4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Depression, delusions, and hallucinations in Alzheimer's disease: no relationship to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Apolipoprotein E and alpha-1-antichymotrypsin genotypes do not predict time to psychosis in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Absence of an apolipoprotein E epsilon4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Cholinesterase Inhibitor Therapies and Neuropsychiatric Manifestations of Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Neuropathologic and neurochemical correlates of psychosis in primary dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Clinical and pathological correlates of apolipoprotein E ?4 in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Psychotic symptoms in Alzheimer's disease are not associated with more severe neuropathologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

Familial Alzheimer Dementia: a prevalent disorder with specific clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

7 January 2021

Behavioural pathology in Alzheimer's disease with special reference to apolipoprotein E genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

7 January 2021

Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

7 January 2021

Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

7 January 2021

A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

7 January 2021

A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

7 January 2021

A SPECT study of delusions in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

7 January 2021

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301148

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1301148

1 reference

13 May 2018

1 reference

13 May 2018